Clinical Trial

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-05-16; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2025-10-08
Trial Details
NCT Number NCT06988488
Lead Sponsor Celgene
Conditions Multiple Myeloma
Enrollment 62 participants
Start Date 2025-10-07
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-28